Prostate Cancer Treatment Overview

Prostate Cancer

Treatment Overview

Several effective treatment options exist today for men diagnosed with prostate cancer. Each man’s particular cancer, overall health, age, and lifestyle will play an important role in determining which option seems most appropriate.

It is the precision of the CyberKnife System with its unique, robotic arm and continual tumor tracking throughout treatment, that make such a difference for patients. In fact, CyberKnife accuracy is sub-millimeter, meaning its pinpoint precision is within the thickness of a dime.


The CyberKnife® System uniquely compensates for prostate movement

The prostate gland can move unpredictably throughout the course of treatment, making the ability to track, detect and correct for motion critically important. In fact, the prostate has been documented to move as much as half an inch in as little as 30 seconds because of normal patient bodily functions – such as filling of the bladder, gas in the bowel, or even slight patient movement during the procedure.1

Unlike any other radiation treatment, the CyberKnife System continually tracks and automatically corrects the beam for movement of the prostate in real-time throughout the entire treatment session. With this automatic motion tracking and adjustment, the CyberKnife System enhances the doctor’s ability to treat with unparalleled preservation of healthy tissue.

The CyberKnife System was cleared by the U.S. Food and Drug Administration in 1999 to treat targets in the head and base of the skull, and in 2001 for treatment outside of the skull. Since then, thousands of patients have been treated with CyberKnife SBRT for prostate cancer.

Treatment Overview Download

CyberKnife® Prostate Cancer Patient Advocate

Dr. Robert Meier and CyberKnife patient Mike “Bing” Crosby take to the air to discuss CyberKnife System treatments for low- to intermediate-risk prostate cancer.

Prostate Cancer Patient Advocate

1. Radiation therapy is completely non-invasive. In some cases, tiny gold markers (fiducials) that help distinguish the tumor from non-cancerous soft tissue are implanted with a minimally invasive procedure.